American Association for Cancer Research
Browse
15417786mcr170519-sup-189564_2_supp_4455504_p11wq1.pdf (319.99 kB)

Supplementary Figure S3 from The Transcription Factor AP4 Promotes Oncogenic Phenotypes and Cisplatin Resistance by Regulating LAPTM4B Expression

Download (319.99 kB)
journal contribution
posted on 2023-04-03, 16:49 authored by Lu Wang, Yue Meng, Jian-Jun Xu, Qing-Yun Zhang

Supplementary Figure S3 shows that knockdown of AP4 by three siRNAs decreased LAPTM4B protein levels in MCF7 and MDA-MB-231 cells.

Funding

National Natural Science Foundation of China

History

ARTICLE ABSTRACT

Lysosomal-associated protein transmembrane-4 beta (LAPTM4B) is a novel oncogene, whose overexpression is involved in cancer occurrence and progression. However, the mechanism of LAPTM4B transcriptional regulation remains unclear. In this study, the results of transcription factor (TF) profiling plate arrays indicated that AP4 was a potential transcription factor regulating LAPTM4B expression. LAPTM4B was positively correlated with AP4 and they were both associated with poor overall and disease-free survival. Luciferase and electrophoretic mobility shift assay assays confirmed that AP4 directly bound to the polymorphism region of LAPTM4B promoter and modulated its transcription. Functionally, AP4 promoted cell proliferation, migration, invasion, and assisted drug resistance in part through upregulation of LAPTM4B. Taken together, these findings identify LAPTM4B as a direct AP4 target gene and the interaction of AP4 and LAPTM4B plays an important role in breast cancer progression.Implications: This study demonstrates that AP4 promotes cell growth, migration, invasion, and cisplatin resistance through upregulation of LAPTM4B expression, thus representing an attractive therapeutic target for breast cancer. Mol Cancer Res; 16(5); 857–68. ©2018 AACR.